MERIT INFO SHEET

Challenges and Solutions for Gene Therapy Trials in Inherited Retinal Diseases

Gene therapy trials in Inherited Retinal Diseases (IRDs) present unique challenges for biopharma drug developers. Choosing MERIT as your clinical endpoint expert gives you access to solutions based on experience supporting 31 gene therapy trials in IRDs.



CHALLENGES

1. **Specialized Measurements**
   IRD clinical trials often entail specialized measurements such as full-field stimuli, microperimetry, and light/dark adaptation testing.
2. **Complex Protocols**
   These studies require highly complex protocols with extensive inclusion/exclusion criteria and long duration.
3. **Numerous Modalities/Timepoints**
   IRD trials also include many imaging modalities such as SD-OCT, CFP, and FAF across numerous timepoints..
4. **Variability**
   Inherent variability in disease progression calls for highly standardized endpoint collection and review.

SOLUTIONS

1. **Experience**
   Our experience in **31** gene therapy trials provides valuable knowledge of specialized measurements.
2. **Training**
   MERIT's thorough, study-specific training supports complex protocols.
3. **EXCELSIOR Platform**
   EXCELSIOR software handles numerous time points and imaging modalities efficiently, providing 24/7 real-time access.
4. **Standard Processes**
   MERIT reduces variability and risk by providing higher quality data through standardized processes.

MERIT
Your Clinical Endpoint Expert

Connect with us to learn more about how our expertise and approach can support bringing your product to market on-time and on-budget. Your success is our priority.

meritcro.com | **E: Info@meritcro.com** | **P: (608) 284-8810**

Inc. 5000 — America's Fastest-Growing Private Companies